Zacks Investment Research
14 Oct 2025, 14:56 UTC · 49w ago
Verdict
Headline leans bullish. We score RLAY +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Wall Street analysts have a mean short-term price target of $13.60 for Relay Therapeutics (RLAY), representing a potential 116.9% upside from its current price of $6.27.
So whatA significant gap between current price and analyst consensus often attracts momentum buyers and indicates strong fundamental optimism.
More positive than 93% of claims this week
There is strong analyst agreement regarding positive earnings estimate revisions for Relay Therapeutics.
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 77% of claims this week
Relay Therapeutics shares have increased by 54.4% over the last four weeks.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The stock has gained significantly, and analysts show strong agreement regarding potential earnings beats and a high mean price target.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+187.6%
Price agrees with the score
$18.03 vs $6.27 close before publication (Oct 13) · not market-adjusted
RLAY chart →
